Cushing's Syndrome
Catching up with Dr. Mario Maldonado: milder hypercortisolism, AI, and what’s ahead
In this episode, Dr. Mario Maldonado from Recordati Rare Diseases discusses recent advances in endocrinology, focusing on hypercortisolism, diagnostic challenges, and innovative treatments. He shares insights from clinical studies and the future of AI in disease management. We touched on the importance of increased awareness of milder forms of hypercortisolism, the challenges of diagnosing subtle endocrine disorders, and the critical impact of AI on data analysis and patient identification.
Adrenal Adenomas
New osilodrostat data in adrenal Cushing’s
From Lewis Blevins, M.D. Medical Director of the California Center for Pituitary Disorders at UCSF and PWN co-founder – a summary of an important study by Dr. Marta Araujo-Castro and others (J Clin Endocrinol Metab 111:2180-2189, 2026) recently published a manuscript titled “International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome.”
Of note:
Crinetics Pharmaceuticals, launches a new resource, Everyday Advocacy, with leading patient groups. Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
Crinetics Pharmaceuticals Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)- Read more
When your pituitary endocrinologist writes science fiction: introducing “2345” – Details here
Dr. Naila Goldenberg speaks about Adrenal Insufficiency and her experiences with cortisol pumps
Adrenalectomy Benefits for People with Mild Autonomous Cortisol Secretion (MACS)
Cortisol and type 2 diabetes
Disorders of cortisol secretion related to adrenal conditions
Most Popular Articles
The Podcast
Knowledge and information are critical tools affecting adrenal disease knowledge and treatments. Join the Adrenal World News podcast, as it navigates the wonders and complexities of adrenal conditions.
At ENDO 2026, Dr. Richard Auchus of the University of Michigan shares his perspectives on the connection between type 2 diabetes and hard-to-control hypertension and high cortisol in Corcept Therapeutics’ landmark studies. The interview covers two related studies investigating how often “common” diseases—difficult-to-control diabetes and hypertension are actually being driven by undiagnosed adrenal dysfunction, particularly mild, clinically significant cortisol excess from adrenal adenomas.
This is a very informative discussion about the new indications of the Cushing's Drug Isturisa® (osilodrostat) with Dr. Mario Maldonado, who heads global development for endocrinology at Recordati Rare Diseases.
Apple Podcasts
Spotify
Amazon Music
Google Podcasts
